Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology

International Journal of Pharmaceutics

Volumn 453, Issue 2, 2013, Pages 300-306

  Wu, Chunnuan ^a   Sun, Le ^a   Sun, Jin ^a   Yang, Yajun ^a   Ren, Congcong ^a   Ai, Xiaoyu ^a   Lian, He ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Formulation optimization; Gastrointestinal simulation technology; GastroPlus ; Lansoprazole; Parameter sensitivity analysis

Indexed keywords

LANSOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DIFFUSION COEFFICIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; ENTERIC COATED TABLET; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SIMULATION TECHNOLOGY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; SINGLE DRUG DOSE; VALIDATION PROCESS;

EID: 84884141596     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.034     Document Type: Article

References (36)

1. Agoram, B., Woltosz, W.S., Bolger, M.B., 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (Suppl. 1), S41-S67. (Pubitemid 32905355)
2. Amidon, G., Lennernas, H., Shah, V., Crison, J., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
3. Dahan, A., Miller, J.M., Hoffman, A., Amidon, G.E., Amidon, G.L., 2009. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J. Pharm. Sci. 99, 2739-2749.
4. De Buck, S.S., Sinha, V.K., Fenu, L.A., Gilissen, R.A., Mackie, C.E., Nijsen, M.J., 2007a. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos. 35, 649-659. (Pubitemid 46513269)
5. De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E., Gilissen, R.A.H.J., 2007b. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35, 1766-1780. (Pubitemid 47481568)
6. Dressman, J.B., Reppas, C., 2010. Oral Drug Absorption: Prediction and Assessment. Informa Healthcare, New York, pp. 15-18.
7. Fu, Q., Kou, L., Gong, C., Li, M., Sun, J., Zhang, D., Liu, M., Sui, X., Liu, K., Wang, S., He, Z., 2012. Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability. Int. J. Pharm. 427, 358-364.
8. Hintz, R.J., Johnson, K.C., 1989. The effect of particle size distribution on dissolution rate and oral absorption. Int. J. Pharm. 51, 9-17. (Pubitemid 19087827)
9. Horn, J., 2000. The proton-pump inhibitors: similarities and differences. Clin. Ther. 22, 266-280. (Pubitemid 30213134)
10. Jiang, W., Kim, S., Zhang, X., Lionberger, R.A., Davit, B.M., Conner, D.P., Yu, L.X., 2011. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int. J. Pharm. 418, 151-160.
11. Jinno, J.-i., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G.G., Higaki, K., Kimura, T., 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111, 56-64. (Pubitemid 43289995)
12. Jones, H.M., Parrott, N., Ohlenbusch, G., Lave, T., 2006. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin. Pharmacokinet. 45, 1213-1226. (Pubitemid 44904824)
13. Juenemann, D., Jantratid, E., Wagner, C., Reppas, C., Vertzoni, M., Dressman, J.B., 2010. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur. J. Pharm. Biopharm. 77, 257-264.
14. Kawano, S., Okada, H., Kawahara, Y., Hori, K., Tanioka, D., Tsuzuki, T., Inoue, M., Yagi, S., Takenaka, R., Yamamoto, K., 2011. Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. Digestion 84, 46-53.
15. Kesisoglou, F., Wu, Y., 2008. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 10, 516-525.
16. Kristl, A., Vrečer, F., 2000. Preformulation investigation of the novel proton pump inhibitor lansoprazole. Drug Dev. Ind. Pharm. 26, 781-783.
17. Kuentz, M., Nick, S., Parrott, N., Rothlisberger, D., 2006. A strategy for preclinical formulation development using GastroPlusTM as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 27, 91-99. (Pubitemid 41728259)
18. Lindenberg, M., Kopp, S., Dressman, J.B., 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58, 265-278. (Pubitemid 39037234)
19. Miller, J.M., Beig, A., Carr, R.A., Spence, J.K., Dahan, A., 2012a. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol. Pharm. 9, 2009-2016.
20. Miller, J.M., Beig, A., Carr, R.A., Webster, G.K., Dahan, A., 2012b. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. Mol. Pharm. 9, 581-590.
21. Miller, J.M., Beig, A., Krieg, B.J., Carr, R.A., Borchardt, T.B., Amidon, G.E., Amidon, G.L., Dahan, A., 2011. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol. Pharm. 8, 1848-1856.
22. Mosharraf, M., Nystrom, C., 1995. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int. J. Pharm. 122, 35-47.
23. Neil Parrott, Lave, T., 2008. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5, 760-775.
24. Norris, D.A., Leesman, G.D., Sinko, P.J., Grass, G.M., 2000. Development of predictive pharmacokinetic simulation models for drug discovery. J. Control. Release 65, 55-62. (Pubitemid 30122915)
25. Noyes, A.A., Whitney, W.R., 1897. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19, 930-934.
26. Oh DM, C.R., Amidon, G.L., 1993. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 10, 264-270.
27. Okumu, A., DiMaso, M., Lobenberg, R., 2009. Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products. Eur. J. Pharm. Biopharm. 72, 91-98.
28. Parrott, N., Lave, T., 2002. Prediction of intestinal absorption: comparative assessment of GastroPlus™ and idea™. Eur. J. Pharm. Sci. 17, 51-61. (Pubitemid 35287171)
29. Schanker, L.S., 1959. Absorption of drugs from the rat colon. J. Pharmacol. Exp. Ther. 126, 283-290.
30. Schanker, L.S., 1960. On the mechanism of absorption of drugs from the gastrointestinal tract. J. Med. Pharm. Chem. 2, 343-359.
31. Štefanič, M., Locatelli, I., Vrečer, F., Sever, T., Mrhar, A., Bogataj, M., 2012. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation. Eur. J. Pharm. Biopharm. 82, 376-382.
32. Tabatar, T., Makino, T., Kashihara, T., Hirai, S., Kitamori, N., Toguchi, H., 1992. Stabilization of a new antiulcer drug (Lansoprazole) in the solid dosage forms. Drug Dev. Ind. Pharm. 18, 1437-1447.
33. Yokoe, J.-i., Iwasaki, N., Haruta, S., Kadono, K., Ogawara, K.-i., Higaki, K., Kimura, T., 2003. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. J. Control. Release 86, 305-313. (Pubitemid 36084276)
34. Yu, L.X., Lipka, E., Crison, J.R., Amidon, G.L., 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 19, 359-376. (Pubitemid 26227526)
35. Zhang, W., 2010. Study on the pharmacokinetics of lansoprazole for injection in chinese healthy volunteers. A thesis for degree of Master. Zhengzhou University, pp. 29-32.
36. Zhang, X., Lionberger, R.A., Davit, B.M., Yu, L.X., 2011. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 13, 59-71.